Evidence map›Paper›PMID 26328914›Full record

ArticleJournal of cancer research and clinical oncology2016

Diagnostic and prognostic value of bladder cancer-related transcript markers in urine.

Juliane Schmidt, Catharina Propping, Woei-Yun Siow, Andrea Lohse-Fischer, Marieta Toma, Anka Baldauf-Twelker, Oliver W Hakenberg, Manfred P Wirth, Susanne Fuessel

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Juliane SchmidtDepartment of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany. juliane.k.schmidt@gmail.com.
Catharina ProppingDepartment of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Woei-Yun SiowDepartment of Urology, Raffles Hospital, 585 North Bridge Road, Singapore, Singapore.
Andrea Lohse-FischerDepartment of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Marieta TomaInstitute of Pathology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Anka Baldauf-TwelkerDepartment of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Oliver W HakenbergDepartment of Urology, University of Rostock, Schillingallee 35, 18057, Rostock, Germany.
Manfred P WirthDepartment of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Susanne FuesselDepartment of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany. susanne.fuessel@uniklinikum-dresden.de.
TU Dresden · DERaffles Institution · SGUniversity of Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSince cytology as the current "gold standard" for noninvasive detection of bladder cancer (BCa) is characterized by a relatively low sensitivity, urinary transcript levels of survivin (SVV), Ki-67 and cytokeratin 20 (CK20) were evaluated as alternative or complementary biomarkers. Furthermore, their prognostic value was investigated.

methodsVoided urine samples from 105 BCa patients and 156 controls were included. Total RNA was isolated from urine pellets and reverse-transcribed into cDNA. Expression levels of SVV, Ki-67 and CK20 were determined by quantitative PCR and normalized to the housekeeping gene TBP. Diagnostic performance of transcript markers and cytology was assessed by receiver operating characteristic (ROC) curve analyses. The prognostic value of the transcript markers was calculated by Cox proportional hazards models.

resultsROC analyses resulted in AUC values between 0.71 (Ki-67) and 0.86 (CK20), indicating an appropriate diagnostic power. Using specifically defined cutoff values, the expression levels of the assessed biomarkers were significantly higher in urine specimens from BCa patients compared to control group (Mann-Whitney U test p < 0.001). Specificity ranged from 75% (SVV) to 84% (CK20) and sensitivity from 56% (Ki-67) to 87% (CK20). In combination with cytology, the sensitivity increased up to 97% (CK20). With regard to prognostic power, only SVV showed a significant, but not independent impact on the risk of recurrence (p = 0.008).

conclusionsQuantitative assessment of tumor-related transcript markers, particularly of CK20, may serve as a noninvasive method to identify patients with BCa. Moreover, SVV appears to be useful as a marker for a high risk of recurrence.

Indexed as

AdultAgedBiomarkers, TumorCase-Control StudiesCohort StudiesFemaleHumansInhibitor of Apoptosis ProteinsKeratin-20Ki-67 AntigenMaleMiddle AgedPrognosisProspective StudiesRNA, MessengerSurvivinBiomarkers, TumorBIRC5 protein, humanInhibitor of Apoptosis ProteinsKeratin-20Ki-67 AntigenRNA, MessengerSurvivinBIRC5CK20Ki-67SurvivinUrineUrothelial carcinoma

Identifiers

PMID26328914
PMCPMC11819347
OpenAlexW1752211687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.